查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010932

肺癌治疗市场：2026-2032年全球市场预测（依治疗分类、癌症类型、分子类型、给药途径、最终用户和分销管道划分）

Lung Cancer Drugs Market by Therapeutic Class, Cancer Type, Molecule Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肺癌治疗市场价值将达到 295.3 亿美元，到 2026 年将成长至 320.7 亿美元，到 2032 年将达到 550.7 亿美元，复合年增长率为 9.31%。

主要市场统计数据
基准年 2025 295.3亿美元
预计年份：2026年 320.7亿美元
预测年份 2032 550.7亿美元
复合年增长率 (%) 9.31%

本书权威地说明了分子科学、免疫肿瘤学的进步以及医疗保健服务的变化如何重塑肺癌治疗策略和优先事项。

在分子科学、不断发展的临床范式和不断变化的医疗服务模式的推动下，肺癌治疗模式正在发生翻天覆地的变化。近年来，我们见证了治疗治疗方法从标准化的细胞毒性疗法转向利用肿瘤生物学特性、免疫调节和精准标靶治疗。在此背景下，临床医生、保险公司和研发人员在治疗方案选择、联合治疗和患者筛选方面面临新的挑战，而这些都依赖先进的诊断技术和基于生物标记的患者登记。

免疫肿瘤学、精准标标靶治疗、门诊治疗和不断发展的诊断技术的发展趋势如何全面改变肿瘤学的临床路径和商业策略。

科学突破已为肺癌的诊断、治疗和管理带来了变革性的变化，并惠及所有医疗机构。针对CTLA-4、PD-1和PD-L1路径的免疫疗法已从小众适应症发展成为许多患者的基础治疗方法，而针对ALK、EGFR和ROS1突变的标靶治疗也已成为分子分型患者群体的第一线治疗策略。同时，将免疫调节剂与化疗或标靶治疗相结合的联合治疗模式正在重新定义疗效预期和毒性管理。

近期美国贸易关税对跨境供应链、临床物流、价格压力以及肿瘤领域的策略性生产选择所产生的累积影响。

美国将于2025年开始实施累积关税，这对全球肺癌治疗药物的供应链、筹资策略和定价产生了连锁反应。依赖跨境供应活性成分、生物製药製剂或成品的製造商面临更高的接收成本，这迫使他们重新与供应商谈判合约、进行区域采购或重新分配产能。因此，采购团队和契约製造製造商不得不重新评估其供应商多元化和库存策略，以减轻这种衝击。

将治疗领域、癌症类型、分子类别、给药途径和通路与商业和临床策略联繫起来的基于细分的关键见解。

细分市场揭示了清晰的临床需求和商业性路径，这要求研发人员和医疗服务提供者采取个人化的方法。按治疗领域划分，市场格局包括化疗、联合治疗、CTLA-4、PD-1 和 PD-L1 抑制剂免疫疗法以及包括 ALK、EGFR 和 ROS1 抑制剂标靶治疗。每个治疗领域都有其独特的疗效特征、安全性考量和监测要求，这些都会影响药物目录和处方模式。按癌症类型划分，非小细胞肺癌和小细胞肺癌具有不同的治疗模式、显着不同的分子特征和治疗反应，导致不同的诊断和治疗路径。

从区域战略观点，将美洲、欧洲、中东和非洲以及亚太地区在监管差异、诊断系统和医疗保健服务模式方面的细微差别与商业化选择联繫起来。

区域趋势对肺癌治疗领域的临床实践、监管预期和商业性可行性有显着影响。在美洲，监管的柔软性、支付方的竞争力以及先进的诊断基础设施促进了免疫疗法和标靶治疗的快速普及。然而，分散的支付方格局要求制定细緻的准入策略并提供可靠的卫生经济学证据。在该地区的大型肿瘤中心和综合医疗网络中，从以急性期治疗为中心的医院护理向门诊和居家治疗的转变尤为显着，迫使企业相应地调整分销和支持服务。

领先的製药和生物技术公司如何整合其研发管线、诊断技术、生产弹性以及基于价值的合同，以在肺癌治疗领域竞争？

主要企业正抛弃单一产品策略，转型为整合式平台，透过深厚的研发管线、诊断伙伴关係和商业性支持，维持长期竞争力。创新企业优先开发单株抗体和小分子药物，以满足不同患者群体的需求，同时投资伴随诊断，以简化基于生物标记的处方流程和监管互动。策略联盟、授权协议和选择性收购等手段常被用于强化产品组合、加速新型作用机制的开发以及扩大生产能力，尤其是在需要特殊生产的生物製药领域。

为加强临床开发、供应链韧性、诊断整合和以支付方为中心的证据生成，提出切实可行的建议，以增强竞争优势。

产业领导企业应采取组合策略，平衡创新、价值链韧性和以支付方为中心的证据产生。优先投资伴随诊断和次世代定序合作，以确保识别出可操作的生物标誌物，从而优化患者选择并增强报销谈判中的价值提案。同时，应实现采购多元化，并探索策略性区域生产和合作生产协议，以减轻关税成本波动的影响，并保障临床试验药物的稳定供应。

采用透明严谨的调查方法，结合专家的直接访谈、二手文献的整合以及资料检验，以检验临床和营运方面的发现。

本调查方法结合了结构化的初步研究、全面的二次研究和严谨的整合，确保了研究结果的稳健性和实用性。初步研究包括对临床专家、药物安全监测专家、供应链负责人和支付方进行深入访谈，并辅以与顾问小组的讨论，以检验对新兴趋势的解读。二次研究涵盖了监管申报文件、同行评审文献、临床试验註册信息、卫生当局的公共指南以及企业资讯披露，并对临床声明、安全性概况和核准流程进行了交叉检验。

总之，综合分析概述了科学进步、诊断准确性和操作调整必须如何融合，才能将治疗可能性转化为可及和永续的护理。

总而言之，目前肺癌治疗的特点是科学快速发展、治疗模式不断演变以及复杂的商业性动态，这些都需要协调一致的策略性应对。免疫疗法和标靶治疗的进步正在改变治疗流程，诊断技术的创新使得患者筛选更加精准。同时，政策变化和贸易趋势也暴露了供应链和定价的脆弱性，因此需要采取积极主动的风险缓解措施。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：肺癌治疗市场依治疗分类

  • 化疗
  • 联合治疗
  • 免疫疗法
    • CTLA-4抑制剂
    • PD-1抑制剂
    • PD-L1抑制剂
  • 分子标靶治疗
    • ALK抑制剂
    • EGFR抑制剂
    • ROS1抑制剂

第九章 按癌症类型分類的肺癌治疗市场

  • 非小细胞肺癌
  • 小细胞肺癌

第十章：以分子类型分類的肺癌治疗药物市场

  • 单株抗体
  • 小分子药物

第十一章 肺癌治疗药物市场：依给药途径划分

  • 口服
  • 肠外

第十二章 肺癌治疗药物市场：依最终用户划分

  • 居家医疗
  • 医院
  • 专科诊所

第十三章 肺癌治疗药物市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十四章 肺癌治疗药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 肺癌治疗药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 肺癌治疗药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国肺癌治疗市场

第十八章：中国肺癌治疗药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mirati Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-434CCDA05288

The Lung Cancer Drugs Market was valued at USD 29.53 billion in 2025 and is projected to grow to USD 32.07 billion in 2026, with a CAGR of 9.31%, reaching USD 55.07 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 29.53 billion
Estimated Year [2026] USD 32.07 billion
Forecast Year [2032] USD 55.07 billion
CAGR (%) 9.31%

An authoritative introduction to how molecular science, immuno-oncology advances and care delivery changes are reshaping lung cancer treatment decisions and priorities

The lung cancer therapeutic landscape is undergoing a dramatic redefinition driven by molecular science, evolving clinical paradigms, and shifting care delivery models. Recent years have seen a transition from one-size-fits-all cytotoxic approaches toward therapies that exploit tumor biology, immune modulation, and precision targeting. Against this backdrop, clinicians, payers, and developers are confronting new choices about sequencing, combination regimens, and patient selection that hinge on diagnostic sophistication and biomarker-driven enrollment.

Consequently, stakeholders must reconcile accelerating scientific progress with practical constraints in access, manufacturing complexity, and regulatory navigation. The interplay between monoclonal antibodies and small molecule drugs, the ascendancy of systemic immunotherapies alongside targeted inhibitors, and the growing role of oral agents in outpatient care are reshaping treatment algorithms. As healthcare systems adapt, the emphasis shifts toward multidisciplinary coordination, real-world evidence generation, and scalable delivery pathways that preserve safety while optimizing outcomes.

This introduction sets the stage for a deeper examination of transformative shifts, policy and tariff implications, segmentation-driven insights, regional dynamics, competitive behaviors, and pragmatic recommendations that collectively inform strategic planning across the lung cancer therapeutics ecosystem.

How immuno-oncology, precision targeting, outpatient delivery trends and evolving diagnostics are collectively transforming clinical pathways and commercial strategies in oncology

Scientific breakthroughs have precipitated transformative shifts in how lung cancer is diagnosed, treated, and managed across care settings. Immunotherapy agents that target CTLA-4, PD-1, and PD-L1 pathways have moved from niche indications to foundational therapies for many patients, and targeted therapies against ALK, EGFR, and ROS1 alterations routinely define first-line strategies for molecularly selected populations. Simultaneously, combination therapy paradigms that pair immunomodulators with chemotherapy or targeted agents are redefining response expectations and toxicity management.

These therapeutic advances coincide with operational shifts: more care is delivered outside the inpatient setting via oral and parenteral regimens tailored to outpatient and homecare administration, while digital health and remote monitoring tools support adherence and adverse event surveillance. Diagnostic capabilities have expanded with next-generation sequencing and liquid biopsy techniques enabling earlier and more precise patient stratification, which in turn elevates the importance of integrated diagnostic-commercial strategies. Regulatory frameworks are adapting to accelerated approvals, real-world evidence requirements, and greater scrutiny of safety signals, creating both opportunities and complexities for developers and providers.

Taken together, these developments demand that stakeholders rethink clinical pathways, supply chain resilience, and stakeholder engagement models to capitalize on therapeutic potential while safeguarding patient access and system sustainability.

The cumulative impact of recent United States trade tariffs on cross-border supply chains, clinical logistics, pricing pressure and strategic manufacturing choices in oncology

The introduction of cumulative tariffs implemented in the United States in 2025 has created a ripple effect across global supply chains, procurement strategies, and pricing arrangements for lung cancer therapeutics. Manufacturers reliant on cross-border supply of active pharmaceutical ingredients, biologic components, or finished goods have faced elevated landed costs that necessitate renegotiation of supplier contracts, regionalized sourcing, or reallocation of production capacity. Consequently, procurement teams and contract manufacturers have had to revisit supplier diversification and inventory strategies to mitigate disruptions.

Clinical trial conduct has also been influenced as sites and sponsors reassess logistics for investigational product distribution, particularly for parenteral biologics that depend on cold-chain integrity. Payers and hospital systems, grappling with margin pressures, have intensified scrutiny of cost-effectiveness and utilization management mechanisms, prompting manufacturers to accelerate value-based contracting approaches and to prepare more robust outcomes data to support reimbursement discussions. In addition, tariffs have encouraged some organizations to invest in domestic manufacturing capabilities or to explore strategic partnerships to insulate supply continuity.

Although tariffs have increased friction, they have also catalyzed adaptive strategies that emphasize regional resilience, regulatory harmonization efforts, and commercial models centered on demonstrable patient benefit. Stakeholders who prioritize supply chain transparency, flexible production, and collaborative contracting are more likely to navigate the evolving trade landscape successfully.

Critical segmentation-driven insights that connect therapeutic classes, cancer types, molecule categories, administration routes and distribution pathways to commercial and clinical strategy

Segmentation illuminates distinct clinical needs and commercial pathways that demand tailored approaches from developers and providers. Based on therapeutic class, the landscape includes chemotherapy alongside combination therapy, immunotherapy with CTLA-4, PD-1, and PD-L1 inhibitors, and targeted therapy encompassing ALK, EGFR, and ROS1 inhibitors; each class carries unique efficacy profiles, safety considerations, and monitoring requirements that influence formulary and prescribing patterns. Based on cancer type, treatment paradigms differ between Non Small Cell Lung Cancer and Small Cell Lung Cancer, where molecular profiling and therapeutic responsiveness vary significantly and drive different diagnostic and care pathways.

Based on molecule type, monoclonal antibodies and small molecule drugs present divergent manufacturing, storage, and administration challenges that affect distribution channels and payer negotiations. Based on route of administration, oral and parenteral therapies require distinct adherence supports and infrastructure, with oral agents often enabling home-based care while parenteral regimens remain tethered to clinic and hospital infusion resources. Based on end user, treatment delivery spans homecare settings, hospitals, and specialty clinics, each imposing different operational workflows, reimbursement codes, and staffing profiles that must be addressed in go-to-market plans.

Finally, based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each shape access, patient convenience, and cost structures. Integrating these segmentation lenses provides a granular perspective on patient journeys, commercial levers, and value communication that can be operationalized across development, market access, and field engagement activities.

Regional strategic perspectives that link regulatory nuance, diagnostic readiness and care delivery patterns across the Americas, Europe Middle East & Africa and Asia-Pacific to commercialization choices

Regional dynamics materially influence clinical practice, regulatory expectations, and commercial viability across the lung cancer therapeutic space. In the Americas, regulatory agility, payer competitiveness, and advanced diagnostic infrastructure support rapid adoption of immunotherapies and targeted agents, while fragmented payer landscapes require nuanced access strategies and robust health economic evidence. Transitioning from acute hospital-centered care to outpatient and home-based administration is especially evident in large oncology centers and integrated delivery networks across this region, prompting firms to calibrate distribution and support services accordingly.

In Europe, the Middle East & Africa, heterogeneous reimbursement models, variable diagnostic capacity, and distinct regulatory pathways shape adoption timelines. Stakeholders in this region contend with differential access to next-generation sequencing and biologic therapies, driving the need for tiered launch strategies and partnerships with regional diagnostic and clinical networks. Meanwhile, in Asia-Pacific, rapid investment in diagnostic capacity, growth of domestic manufacturing, and strong government interest in expanding cancer care access are creating fertile conditions for both global and local players to pursue innovative collaborations. Across regions, localized pricing pressures and supply chain considerations necessitate adaptive commercial approaches that reflect regional infrastructure, regulatory nuance, and payer priorities.

Ultimately, regional insight should inform prioritization of clinical development, market entry sequencing, and partnership models so that resources align with patient needs and systemic capabilities.

How leading pharmaceutical and biotechnology companies are integrating pipelines, diagnostics, manufacturing resilience and value-based contracting to compete in lung cancer therapeutics

Leading companies are evolving beyond single-product strategies toward integrated platforms that combine pipeline depth, diagnostic partnerships, and commercial support to sustain long-term competitiveness. Innovative firms are prioritizing development of both monoclonal antibodies and small molecule agents to address complementary patient populations, while investing in companion diagnostics to secure biomarker-driven prescribing and to streamline regulatory interactions. Strategic alliances, licensing agreements, and selective acquisitions are frequently used to bolster portfolios, accelerate access to novel mechanisms of action, and expand manufacturing capabilities, particularly for biologics that require specialized production.

Operationally, companies are building capabilities in cold-chain logistics, patient support programs, and digital therapeutics that enhance adherence and real-world outcomes reporting. They are also negotiating outcome-based contracts with payers and health systems, placing emphasis on longitudinal evidence generation and registries to demonstrate value. At the same time, resource allocation increasingly favors therapies with clear biomarker-driven patient selection, improved tolerability, or significant quality-of-life benefits, reflecting payer expectations and clinical demand.

As competition intensifies, corporate differentiation will derive from the ability to integrate clinical science with pragmatic commercialization, manufacturing resilience, and compelling evidence of patient-centered benefit.

Practical and actionable recommendations that align clinical development, supply chain resilience, diagnostics integration and payer-focused evidence generation to strengthen competitive positioning

Industry leaders should adopt a portfolio approach that balances innovation with supply chain resilience and payer-aligned evidence generation. Prioritize investment in companion diagnostics and next-generation sequencing partnerships to ensure actionable biomarker identification, which in turn optimizes patient selection and strengthens value propositions during reimbursement negotiations. Simultaneously, diversify sourcing and consider strategic regional manufacturing or co-manufacturing agreements to reduce exposure to tariff-driven cost volatility and to support reliable clinical trial supply.

Operationally, expand capabilities for outpatient and home-based administration through patient support programs, telehealth integration, and adherence monitoring solutions that reduce healthcare system burden and improve therapeutic continuity. Strengthen commercial arguments by collecting prospective real-world evidence and constructing outcomes-based contracting frameworks that align payment with measurable clinical benefit. Finally, pursue collaborative research with academic centers and health systems to design pragmatic clinical studies that address unmet clinical questions, safety in diverse populations, and comparative effectiveness, thereby enhancing dialogue with regulators and payers about meaningful endpoints.

A transparent and rigorous research methodology integrating primary expert interviews, secondary literature synthesis and data triangulation to validate clinical and operational insights

The research methodology combines structured primary research, comprehensive secondary review, and rigorous synthesis to ensure findings are robust and actionable. Primary research included in-depth interviews with clinical specialists, pharmacovigilance experts, supply-chain leaders, and payers, complemented by advisory-panel discussions to validate interpretation of emergent trends. Secondary research encompassed regulatory filings, peer-reviewed literature, clinical-trial registries, published guidance from health authorities, and company disclosures to cross-check clinical claims, safety profiles, and approval pathways.

Data integration relied on triangulation to reconcile disparate sources and to surface consistent signals about treatment adoption, operational challenges, and strategic behaviors. Where appropriate, sensitivity analyses were performed to test assumptions and to understand the implications of policy changes, including tariff effects on supply and distribution. Limitations of the approach are acknowledged: real-world practice can evolve rapidly, and emerging clinical trial data may alter therapeutic positioning. Therefore, the methodology emphasizes transparency in data sources, stakeholder validation, and continual monitoring to maintain relevance as the landscape evolves.

A concluding synthesis outlining how scientific progress, diagnostic precision and operational adaptations must coalesce to convert therapeutic promise into accessible and sustainable care

In summary, the lung cancer therapeutic landscape is characterized by rapid scientific progress, shifting delivery models, and complex commercial dynamics that require coordinated strategic responses. Advances in immunotherapy and targeted agents are altering treatment algorithms while diagnostic innovation enables more granular patient selection. At the same time, policy shifts and trade dynamics have exposed vulnerabilities in supply chains and pricing that necessitate proactive mitigation measures.

Stakeholders who align biomarker-driven development with pragmatic distribution strategies, invest in domestic or regional manufacturing resilience, and embrace outcomes-based engagement models with payers will be better positioned to deliver sustained patient benefit. Cross-functional collaboration among developers, diagnostics providers, providers, and payers is essential to translate therapeutic potential into accessible, safe, and economically sustainable care. Continued surveillance of clinical trial results, regulatory decisions, and regional access dynamics will be critical to iteratively refine strategy and to ensure that innovations reach the patients who can benefit most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Drugs Market, by Therapeutic Class

  • 8.1. Chemotherapy
  • 8.2. Combination Therapy
  • 8.3. Immunotherapy
    • 8.3.1. Ctla-4 Inhibitors
    • 8.3.2. Pd-1 Inhibitors
    • 8.3.3. Pd-L1 Inhibitors
  • 8.4. Targeted Therapy
    • 8.4.1. Alk Inhibitors
    • 8.4.2. EgfR Inhibitors
    • 8.4.3. Ros1 Inhibitors

9. Lung Cancer Drugs Market, by Cancer Type

  • 9.1. Non Small Cell Lung Cancer
  • 9.2. Small Cell Lung Cancer

10. Lung Cancer Drugs Market, by Molecule Type

  • 10.1. Monoclonal Antibodies
  • 10.2. Small Molecule Drugs

11. Lung Cancer Drugs Market, by Route Of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Lung Cancer Drugs Market, by End User

  • 12.1. Homecare Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Lung Cancer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Lung Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Lung Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Lung Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Lung Cancer Drugs Market

18. China Lung Cancer Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. AstraZeneca PLC
  • 19.7. Bayer AG
  • 19.8. BeiGene, Ltd.
  • 19.9. Blueprint Medicines Corporation
  • 19.10. Bristol-Myers Squibb Company
  • 19.11. Daiichi Sankyo Company, Limited
  • 19.12. Eli Lilly and Company
  • 19.13. Genentech, Inc.
  • 19.14. Gilead Sciences, Inc.
  • 19.15. GlaxoSmithKline plc
  • 19.16. Janssen Biotech, Inc.
  • 19.17. Johnson & Johnson
  • 19.18. Merck & Co., Inc.
  • 19.19. Mirati Therapeutics, Inc.
  • 19.20. Novartis AG
  • 19.21. Pfizer Inc.
  • 19.22. Roche Holding AG
  • 19.23. Sanofi S.A.
  • 19.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GCC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. GCC LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GCC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. G7 LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. G7 LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. G7 LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. NATO LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. NATO LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. NATO LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)